XtalPi receives $51m initial payment from DoveTree collaboration

XtalPi Holdings has received an initial $51 million payment from its AI-driven drug discovery agreement with DoveTree Medicines.

The partnership covers small molecule and antibody candidates across various disease areas using XtalPi's AI platform. XtalPi is eligible for a further $49 million payment, up to $5.89 billion in milestone payments, and single-digit percentage royalties on net sales.